Susquehanna International Group, LLP Neu Base Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	SELL	$0.17 - $0.39 $3,166 - $7,264	-18,627 Reduced 49.16%	19,264 $3,000
Q4 2022 Feb 14, 2023	BUY	$0.18 - $0.3 $6,820 - $11,367	37,891 New	37,891 $7,000
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $15,037 - $35,394	-18,339 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.26 - $2.95 $19,143 - $44,819	-15,193 Reduced 45.31%	18,339 $34,000
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $78,561 - $126,302	-30,216 Reduced 47.4%	33,532 $94,000
Q3 2021 Nov 15, 2021	BUY	$3.27 - $4.76 $77,845 - $113,316	23,806 Added 59.6%	63,748 $230,000
Q2 2021 Aug 11, 2021	SELL	$4.63 - $7.34 $123,977 - $196,543	-26,777 Reduced 40.13%	39,942 $191,000
Q1 2021 May 17, 2021	BUY	$6.92 - $12.36 $186,445 - $333,015	26,943 Added 67.74%	66,719 $493,000
Q4 2020 Feb 16, 2021	BUY	$6.92 - $9.25 $275,249 - $367,928	39,776 New	39,776 $278,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.